Compare · AZN vs INCR
AZN vs INCR
Side-by-side comparison of AstraZeneca PLC (AZN) and Intercure Ltd. (INCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and INCR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $265.93B, about 3912.7x INCR ($68.0M).
- Over the past year, AZN is up 104.7% and INCR is down 33.8% - AZN leads by 138.5 points.
- AZN has hit the wire 17 times in the past 4 weeks while INCR has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 1 for INCR).
- Company
- AstraZeneca PLC
- Intercure Ltd.
- Price
- $172.10+0.36%
- $5.03-5.45%
- Market cap
- $265.93B
- $68.0M
- 1M return
- +3.30%
- -11.91%
- 1Y return
- +104.72%
- -33.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 1
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Intercure Ltd.
InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- Gabelli To Host 8th Annual Healthcare Symposium
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
- ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
- SEC Form 6-K filed by AstraZeneca PLC
Latest INCR
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Amendment: SEC Form 6-K/A filed by Intercure Ltd.
- SEC Form 6-K filed by Intercure Ltd.
- SEC Form 4 filed by Chief Financial Officer Cohen Amos
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
- SEC Form D filed by Intercure Ltd.
- InterCure Ltd. Announces 1-for-5 Reverse Share Split
- SEC Form 6-K filed by Intercure Ltd.